• Policy
• “Impartiality of reimbursement review system undermined"
• by Lee, Jeong-Hwan Oct 18, 2021 05:54am

• Policy
• Introduction of CDF for Zolgensma was proposed
• by Lee, Hye-Kyung Oct 18, 2021 05:54am

• Policy
• The HIRA also decided to disclose the results of Kymriah
• by Lee, Hye-Kyung Oct 15, 2021 05:58am

• Policy
• Requests for confirmation of medical expenses, disclosed
• by Lee, Hye-Kyung Oct 15, 2021 05:57am

• Policy
• A new drug preferential law will be promoted
• by Lee, Jeong-Hwan Oct 15, 2021 05:57am

• Policy
• No need to extend the benefit period of Keytruda
• by Lee, Jeong-Hwan Oct 14, 2021 05:38am

• Policy
• Poor ‘Benefit Adequacy Assessment' in controversy
• by Lee, Jeong-Hwan Oct 14, 2021 05:38am

• Policy
• # of COVID-19 confirmed medical staff doubled in 3 months
• by Lee, Jeong-Hwan Oct 14, 2021 05:37am

• Policy
• Suspicions of preferential tx for SK Bioscience & Celltrion
• by Lee, Tak-Sun Oct 14, 2021 05:37am

• Policy
• MFDS will quickly & thoroughly verify Merck's COVID-19 tx
• by Lee, Tak-Sun Oct 13, 2021 05:46am